Palvella Therapeutics, Inc. (PVLA) Gets More FDA Orphan Funding; NDA Filed for QTORIN
Palvella received a third year of FDA Orphan Products grant funding supporting its Phase 3 SELVA program for QTORIN rapamycin. The NDA has been completed following positive Phase 3 results; potential U.S. launch in H1 2027, if approved.Material DetailsContext by AI AnalystThis is a late-stage updat…